Detailed narrative
Dual Commercial Strategy and Restructuring Success
Q2 2026 marked the one-year anniversary of Amarin's dual commercial strategy, combining a U.S. company-managed presence with a fully partnered international platform. This strategy, coupled with completed restructuring activities, has resulted in a significantly lower cost base, achieving approximately $70 million in annual cost savings.
The refined organizational structure aims to enhance efficient execution of the long-term growth strategy and has enabled the company to provide a full-year 2026 outlook for key metrics.
International Expansion and Partner Performance
VASCEPA was commercially available in 22 countries as of June 30, 2026. The accelerating international growth is primarily driven by the exclusive license and supply agreement with Recordati, covering 59 countries in Europe, and six other commercial partnerships globally. Cumulative year-over-year volume for in-market demand across the global partner network rose by 59%.
VAZKEPA is commercialized in 11 European countries, with recent launch in Romania, and Recordati's efforts led to a 69% increase in European in-market demand in Q2 2026 from Q2 2025.
U.S. Market Performance and Payer Exclusivity
In the U.S., VASCEPA maintains a leading position in the icosapent ethyl (IPE) market despite ongoing generic pressure. The U.S. IPE market grew by 3% in Q2 2026 compared to Q2 2025. VASCEPA's market share increased to 48% as of June 30, 2026, up from 43% in the prior year.
Branded prescriptions rose 14% year-over-year in Q2 2026, reflecting commercial execution. The company expects to maintain exclusivity with key payers through the end of 2026, ensuring continued profitability and cash generation from the U.S. business.
Scientific Advancements and Regulatory Support
Amarin continues to invest in scientific research, with new data from a post-hoc analysis of the REDUCE-IT trial presented at the European Atherosclerosis Society Congress. This analysis highlighted the value of risk-weighted apolipoprotein B (apo B) in identifying patients with residual cardiovascular risk.
High-dose icosapent ethyl is formally recommended in leading international treatment guidelines, including the 2026 ACCAHA multi-society dyslipidemia guideline. The company's R&D and medical affairs teams provide critical expertise to partners, supporting regulatory submissions and scientific exchange globally.
Financial Position and Capital Deployment
The company ended Q2 2026 with a strong cash and investments balance of $314.6 million, up from $303 million at year-end 2025, and no debt. It generated $7 million in positive cash flow from operations, marking the third consecutive quarter of positive cash flow.
The previously authorized share repurchase program, approved through Q2 2029, remains in effect. Management is evaluating capital deployment options to benefit shareholders, including potential M&A opportunities, and is working with Barclays as its financial adviser.
Inventory Management and Cost of Goods Sold
Disciplined inventory management is a high operational priority, contributing to cash flow. Inventory declined by $19.5 million from March 31, 2026, and by $31.8 million from December 31, 2025. Cost of goods sold increased to $27.2 million in Q2 2026, up 22% from $22.4 million in Q2 2025, primarily due to increased product volumes associated with regaining an exclusive PBM relationship in the U.S. in Q3 2025.
The company expects COGS to stabilize as volumes level off.